Last update Aug. 6, 2017

Ombitasvir

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Used in the treatment of hepatitis C, usually in combination with other antivirals.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016), other experts believe that treatment with Ombitasvir, on its own or in combination with paritaprevir and ritonavir or with Paritaprevir, Ritonavir and Desabuvir is not contraindicated during breastfeeding (LactMed 2016).


See below the information of these related products:

  • Maternal Hepatitis C Infection (Safe substance and/or breastfeeding is the best option.)
  • Paritaprevir (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Ritonavir (RTV, /r) (Safe substance and/or breastfeeding is the best option.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Ombitasvir in other languages or writings:

Group

Ombitasvir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ombitasvir in its composition:

  • Holkira ™. Contains other elements than Ombitasvir in its composition
  • Technivie™. Contains other elements than Ombitasvir in its composition
  • Viekira™. Contains other elements than Ombitasvir in its composition
  • Viekirax™. Contains other elements than Ombitasvir in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 894 daltons
Protein Binding 99.9 %
Tmax 4 - 5 hours
T½ 21 - 25 hours

References

  1. EMA. Ombitasvir-Paritaprevir-Ritonavir. Drug Summary. 2017 Full text (in our servers)
  2. EMA. Ombitasvir-Paritaprevir-Ritonavir. Ficha técnica. 2017 Full text (in our servers)
  3. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016 Abstract Full text (link to original source) Full text (in our servers)
  4. Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  5. LactMed. Ombitasvir. Full Record Display. 2016 Full text (in our servers)

Total visits

2,766

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM